Accelerated prime-and-trap vaccine regimen in mice using repRNA-based CSP malaria vaccine.

ABSTRACT: Malaria, caused by Plasmodium parasites, remains one of the most devastating infectious diseases worldwide, despite control efforts that have lowered morbidity and mortality. The only P. falciparum vaccine candidates to show field efficacy are those targeting the asymptomatic pre-erythrocytic (PE) stages of infection. The subunit (SU) RTS,S/AS01 vaccine, the only licensed malaria vaccine to date, is only modestly effective against clinical malaria. Both RTS,S/AS01 and the SU R21 vaccine candidate target the PE sporozoite (spz) circumsporozoite (CS) protein. These candidates elicit high-titer antibodies that provide short-term protection from disease, but do not induce the liver-resident memory CD8⁺ T cells (Trm) that confer strong PE immunity and long-term protecti

SUBMITTER: MacMillen Z 

PROVIDER: S-EPMC10350175 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature